Table 2.
Effect of TCC on PBMCs proliferation, cytotoxic activity and immune cells – comparisons between control group at t = 0 and at t = 16 week, and between TCC group at t = 0 and at t = 16 week
| Control | TCC | |||
|---|---|---|---|---|
| t = 0 | t = 16 weeks | t = 0 | t = 16 weeks | |
| PBMCs proliferation (OD at 570 nm) | ||||
| 0.5 × 106 | 0.89 ± 0.26 | 0.99 ± 0.25 | 0.70 ± 0.28 | 0.92 ± 0.24* |
| 1 × 106 | 1.33 ± 0.26 | 1.39 ± 0.18 | 1.21 ± 0.23 | 1.66 ± 0.37‡ |
| PBMCs cytolytic activity (A549 viability; OD at 450 nm) | ||||
| 50:1 E:T ratio | 1.04 ± 0.33 | 0.99 ± 0.25 | 1.04 ± 0.19 | 0.51 ± 0.15‡▲ |
| 25:1 E:T ratio | 0.85 ± 0.39 | 0.76 ± 0.22 | 0.85 ± 0.16 | 0.51 ± 0.13‡▲ |
| 12.5:1 E:T ratio | 0.66 ± 0.20 | 0.63 ± 0.20 | 0.53 ± 0.15 | 0.52 ± 0.20 |
| Immune cells | ||||
| NK (%) | 20.49 ± 6.82 | 20.17 ± 7.35 | 22.66 ± 8.23 | 27.94 ± 10.3▲ |
| NKT (%) | 3.89 ± 2.59 | 2.87 ± 1.71 | 3.58 ± 2.97 | 3.83 ± 3.03 |
| DC11c+ DCs (%) | 1.63 ± 0.80 | 1.47 ± 0.61 | 2.37 ± 1 | 3.09 ± 1.57 |
| DC123+ DCs (%) | 0.42 ± 0.22 | 0.63 ± 0.38 | 0.95 ± 0.44 | 1.10 ± 0.58 |
Values are expressed as mean ± SD. Significant differences between t = 0 week and t = 16 week in control group as well as in TCC group are indicated as follows: *p < 0.05; ‡p < 0.001, using paired-samples t-test. Significant differences between TCC group and control group at t = 16 week are indicated as ▲ p < 0.05, using independent samples t-test.